Subventions et des contributions :

Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019).

COMPANY BACKGROUND: ViVitro Labs Inc. is a Canadian-based company that has providedx000D
cardiovascular and endovascular device test equipment and laboratory testing to a global market. It is the onlyx000D
Canadian company making cardiovascular and endovascular device test simulators. The ViVitro Pulsex000D
Duplicator system is the world's most cited and used in vitro hemodynamic testing system for commercial heartx000D
and valve devices. THE NEED: Although the ViVitro simulators have the capability of testing somex000D
cardiovascular diseases and cardiovascular devices, they do not have the capability of testing the mostx000D
important and common congenital cardiovascular pathology: coarctation of the aorta (COA). COA is ax000D
narrowing of the aorta with many morphologic variants. A physical COA simulator is much needed forx000D
designing, developing, evaluating and optimizing COA-related devices, especially the emerging vascularx000D
transcatheter stents, and for developing novel diagnostic methods for COA. COLLABORATIONx000D
OPPORTUNITY: This collaboration allows ViVitro to investigate feasibility of adding the capability of testingx000D
of COA and COA-related devices to its product portfolio using an innovative approach. METHODOLOGY:x000D
This project uses clinical imaging data, image processing algorithms, and a unique computational fluidx000D
dynamics and lumped parameter modeling framework to provide details of the physiological pulsatile flow andx000D
pressures through the heart and the circulatory system. This information is required for developing andx000D
validating the setup to simulate the physiological condition. OPPORTUNITY: The new simulator can servex000D
testing needs of medical-device companies that want to introduce new devices for COA. This simulator is alsox000D
very attractive for academic research worldwide. This is particularly important because the industrial focus onx000D
vascular transcatheter stents and related devices is rapidly growing and the number of companies developingx000D
new vascular devices is greatly increasing. The new simulator can help ViVitro Labs to differentiate in thex000D
international market of endovascular device simulators and can create new jobs in Canada.